(800)525-7111 Free Consultation

Zantac COVID-19 Risk: What You Need to Know

Riddle Brantley LLP   |  July 9, 2020   |  

Does Zantac increase the risk of contracting the coronavirus? A new study suggests there is a significant Zantac COVID-19 risk and that those who take other heartburn medications may also be at increased coronavirus risk. 

Zantac COVID-19 Risk - Riddle & BrantleyAccording to a new study published in the American Journal of Gastroenterology, a disproportionate number of people who contracted COVID-19 reported symptoms of gastroesophageal reflux disease, also known as GERD or more commonly, “heartburn.” More alarming, however, is the apparent connection between proton pump inhibitors — medications used to treat ulcers and heartburn — and COVID-19 risk. The study raises serious concerns about potential Zantac coronavirus risk.

In this blog post, we’ll examine the possible link between Zantac and COVID-19 (coronavirus).

Zantac COVID-19 Risk: What the Research Says

Researchers described the study detailing potential Zantac COVID-19 risk as unsurprising. That’s because proton pump inhibitors (PPIs) and H2 blockers (like Zantac) reduce stomach acid production, and this acid is one of the body’s natural defenses against potentially harmful bacteria and viruses like the coronavirus.

Does Zantac Increase the Risk of Coronavirus - Riddle & BrantleyThat said, according to a report in TIME, lead researcher Dr. Brennan Spiegel was surprised by “just how large the effect seemed to be.”

Spiegel noted that “the stronger the medicine, the higher the dose, the higher the effect for COVID-19.”

Does Zantac increase the risk of contracting the coronavirus?

To be clear, taking Zantac or another heartburn medication does not mean you will contract COVID-19. However, the recent study suggests that these medications, including Zantac, can significantly increase your risk of contracting the coronavirus.

Those taking Zantac or another heartburn medication should consider potential COVID-19 risk in addition to other potential risk factors (see below).

Another Zantac Risk: Cancer

The potential increased Zantac COVID-19 risk comes after the FDA recalled Zantac and generic ranitidine from the market due to “unacceptable” levels of NDMA, a dangerous chemical that is known to cause cancer.

The NDMA in Zantac has been linked to as many as 20 different types of cancer, including many cancers of the gastrointestinal tract, including esophageal cancer, stomach cancer, bladder cancer, pancreatic cancer, kidney cancer and liver cancer, among others. Learn more about potential Zantac cancer risks and protect yourself and your loved ones.

Zantac Cancer Risk - Zantac Cancer Lawyers - Riddle & BrantleyIf you or a loved one has taken brand-name Zantac and been diagnosed with a qualifying cancer, you may be entitled to significant financial compensation.

Our Zantac cancer lawyers are actively investigating these claims and we would love to help you get the justice and compensation you deserve.

For a FREE consultation concerning a potential Zantac claim or lawsuit, please call 1-800-525-7111.

IMPORTANT: A federal judge recently ruled against lawsuits concerning generic Zantac. At this point, we can only accept cases concerning use of brand-name Zantac OR “mixed” use of brand-name Zantac and generic equivalents.

A Riddle & Brantley attorney will listen to you, advise you on your best legal options, and if you decide to hire us, we will fight tirelessly for your right to justice and compensation for cancer potentially suffered due to brand-name Zantac or a mix of brand-name and generic drugs.

Please call 1-800-525-7111 today and let’s review your claim. Our attorneys have recovered millions in compensation for injury victims and we would love to help however we can (see disclaimer below).

In addition to potential Zantac COVID-19 risk, NDMA contamination in Zantac may cause cancer. We believe Justice Counts for victims of dangerous drugs and we are committed to holding pharmaceutical companies accountable for their potential negligence.


***Disclaimer: No settlement agreement has been reached in any litigation regarding ranitidine (ZANTAC®), including in the Multidistrict Litigation in the United States District Court for the Southern District of Florida (case no. 20-MD-2924). 

*** Disclaimer: The results mentioned are intended to illustrate the type of cases handled by the firm. These results do not guarantee a similar outcome, and they should not be construed to constitute a promise or guarantee of a particular result in any particular case. Every case is different, and the outcome of any case depends upon a variety of factors unique to that case.